Clarus Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Clarus Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4,000	Closed	-$853K	–	137
2021 Q1	$853K	Hold	4,000	–	–	0.53%	40
2020 Q4	$939K	Hold	4,000	–	–	0.62%	33
2020 Q3	$1.04M	Hold	4,000	–	–	0.81%	29
2020 Q2	$1.2M	Hold	4,000	–	–	1.01%	22
2020 Q1	$953K	Hold	4,000	–	–	0.95%	21
2019 Q4	$921K	Hold	4,000	–	–	0.61%	35
2019 Q3	$678K	Buy	+4,000	New	+$708K	0.5%	44

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Clarus Wealth Advisors's VRTX Position: Q2 2021 in Review

Clarus Wealth Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2021, closing a stake of 4,000 shares — an estimated $853K sold.

Clarus Wealth Advisors first reported a position in VRTX in Q3 2019 and held it in 7 quarters. The position peaked at $1.2M in Q2 2020. 977 funds tracked by Wall St. Rank hold VRTX as of Q2 2021.

Clarus Wealth Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Clarus Wealth Advisors sold 4,000 Vertex Pharmaceuticals shares in Q2 2021, an estimated $853K.
Clarus Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q3 2019 and held it in 7 quarters.
Clarus Wealth Advisors's Vertex Pharmaceuticals position peaked at $1.2M in Q2 2020.
977 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2021.

Based on Clarus Wealth Advisors's 13F filing for Q2 2021, filed 13 Jul 2021.